NASDAQ:FLNA Cassava Sciences Q4 2025 Earnings Results & Report $0.53 +0.05 (+11.15%) As of 02:47 PM Eastern Cassava Sciences beat analyst earnings expectations in its Q4 2025 results, released March 12, 2026. The company reported EPS of -$0.26 versus the -$0.30 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 12, 2026TimeBefore Market OpensConference Call DateMarch 17, 2026Conference Call10:30 AM ET Cassava Sciences EPS ResultsActual EPS-$0.26Consensus EPS -$0.30Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersCassava Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Cassava Sciences Q4 2025 Earnings FAQ Did Cassava Sciences beat earnings estimates for Q4 2025? Cassava Sciences (NASDAQ:FLNA) reported earnings of -$0.26 per share for Q4 2025, beating the consensus estimate of -$0.30. The report was announced on Thursday, March 12, 2026. Cassava Sciences Earnings HeadlinesCassava Sciences (NASDAQ:FLNA) Stock Sees Heavy Call Option BuyingNovember 11, 2026 | americanbankingnews.comFilana Therapeutics to Participate in the 2026 Maxim Growth SummitOctober 9, 2026 | globenewswire.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 18 at 1:00 AM | Behind the Markets (Ad)Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research ForwardSeptember 22, 2026 | benzinga.comFilana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related EpilepsySeptember 22, 2026 | globenewswire.comFilana Therapeutics, Inc.(NasdaqCM:FLNA) dropped from S&P Global BMI IndexSeptember 20, 2026 | marketscreener.comMSee More Cassava Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email. Email Address About Cassava SciencesCassava Sciences (NASDAQ:FLNA) is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences. Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests. Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018. It is headquartered in Austin, Texas, and has been led by founder and chief executive Remi Barbier.View Cassava Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles General Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a BreakoutAmazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.